Product Development Progress - The company is advancing its antiviral product, Oseltamivir raw material and capsules, as planned [2] - The Ferrous Fumarate raw material has been approved for market launch in December 2025, aimed at preventing and treating iron deficiency anemia, thereby enriching the product pipeline [2] Financial Situation - On January 7, 2026, the company's main capital net inflow was 2.074 million yuan, indicating a shift from net outflow to net inflow compared to the previous trading day, suggesting a potential strengthening of short-term market sentiment [3] - A similar net inflow was observed on January 5, indicating a trend in capital movement [3] Company Fundamentals - For the first three quarters of 2025, the company achieved a revenue of 481 million yuan and a net profit attributable to shareholders of 91.9 million yuan, showing a year-on-year decline [4] - Investors should pay attention to the upcoming periodic financial reports for further insights [4] Industry Policy and Environment - The pharmaceutical and biotechnology industry has long-term development potential due to aging population and policy support, but individual stock performance may be influenced by industry policy dynamics and the company's own R&D investments [5]
新天地抗流感药物研发推进，主力资金近期转为净流入